Clinical Dilemmas in Primary Liver Cancer

List of Contributors. Preface. Part 1: Learning from a Worldwide Perspective. 1 Are patterns and prevalence changing? (Hashem B. El-Serag). 2 Why is the tumour different in Africa? (Nimzing G. Ladep). 3 Control by vaccination: Asian and Taiwan experience (Jia-Horng Kao). 4 The view from the UK (Shahid A. Khan, Mireille B. Toledano, Abigail Zabron, Mehtan Ahmed, and Simon D. Taylor-Robinson). 5 The view from the United States (Hitoshi Maruyama and Arun J. Sanyal). 6 New challenges of NAFLD and HIV epidemics (Quentin M. Anstee and Janice Main). Part 2: Influence of Tumour Characteristics. 7 Controversies in Pathology (Tania Roskams). 8 Not to forget the unusual tumour (Bernard C. Portmann). 9 What can be learned from molecular diagnostic techniques and genetic signatures? (Tariq Moatter and Saeed Hamid). Part 3: Complexities of Patient Assessment and Scoring Systems. 10 Looking after the liver as well as the tumour (Roger Williams). 11 Comparative performances of staging systems for hepatocellular cancer: Early HCC considerations (Peter D. Peng, Timothy M. Pawlik). 12 Rival scoring systems: Do they offer more? (Angelo Sangiovanni and Massimo Colombo). 13 Is it possible to detect early lesions effectively? (Ryota Masuzaki and Masao Omata). 14 What is the value of country based surveillance programmes? (Peter Ott). Part 4: Choice of Radiological Diagnostic Technique. 15 Computed tomography or magnetic resonance imaging for the diagnosis of hepatocellular carcinoma (Wladyslaw Gedroyc). 16 Is Microbubble ultrasound useful? (Adrian Lim). 17 Value of PET scanning (Tara Barwick, Imene Zerizer, and Adil Al-Nahhas). Part 5: Can Treatment be Tailored to the Patient? 18 Who could benefit from chemoembolisation? (Gisele N'Kontchou, Olivier Seror, and Michel Beaugrand). 19 Are drug eluting beads (DEB) worth using? (C. N. Hacking and Pradesh Kumar). 20 What's the future of image-guided radiofrequency ablation for hepatocellular carcinoma? (Riccardo Lencioni). 21 Alternative ablation techniques for hepatocellular carcinoma (John Karani). 22 Justification for Sorafenib and chemotherapy (Philip J. Johnson). 23 When to consider surgery? (Emmanuel Melloul, Mickael Lesurtel, and Pierre-Alain Clavien). 24 Transplant considerations (Myron Schwartz). Part 6: What Does the Future Hold? 25 Dipstick markers for diagnosis: Feasible or not? (Mohamed I. F. Shariff and Simon D. Taylor-Robinson). 26 Targeted gene therapy for hepatocellular carcinoma (HCC): A reality? (Christopher Binny, Marco Della Peruta, and Amit C. Nathwani). 27 Is immune modulation a possibility? (Tim F. Greten and Firouzeh Korangy). 28 Systemic therapy for hepatocellular carcinoma: Future directions (Daniel H. Palmer, Matthew Cramp).